
==== Front
Sci Rep
Sci Rep
Scientific Reports
2045-2322
Nature Publishing Group UK London

39232030
71481
10.1038/s41598-024-71481-5
Article
Phosphorylated Tau at T181 accumulates in the serum of hibernating Syrian hamsters and rapidly disappears after arousal
León-Espinosa G. gonzalo.leonespinosa@ceu.es

14
Murillo A. M. M. 25
Turegano-Lopez M. 47
DeFelipe J. 347
Holgado M. 256
1 https://ror.org/00tvate34 grid.8461.b 0000 0001 2159 0415 Departamento de Química y Bioquímica, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, 28660 Boadilla del Monte, Madrid Spain
2 grid.5690.a 0000 0001 2151 2978 Optics, Photonics and Biophotonics Group, Centre for Biomedical Technology, Campus de Montegancedo Universidad Politécnica de Madrid, 28223 Pozuelo de Alarcón, Madrid Spain
3 grid.419043.b 0000 0001 2177 5516 Instituto Cajal, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain
4 https://ror.org/03n6nwv02 grid.5690.a 0000 0001 2151 2978 Laboratorio Cajal de Circuitos Corticales, Centro de Tecnología Biomédica, Universidad Politécnica de Madrid, Madrid, Spain
5 https://ror.org/014v12a39 grid.414780.e Group of Organ and Tissue on-a-chip and In-Vitro Detection, Health Research Institute of the Hospital Clínico San Carlos, IdISSC. C/Profesor Martín Lagos s/n, 4ª Planta Sur, 28040 Madrid, Spain
6 https://ror.org/03n6nwv02 grid.5690.a 0000 0001 2151 2978 Applied Physics and Materials Engineering Department, Escuela Técnica Superior de Ingenieros Industriales, Universidad Politécnica de Madrid, C/José Gutierrez Abascal, 2, 28006 Madrid, Spain
7 grid.413448.e 0000 0000 9314 1427 Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, 28031 Madrid, Spain
4 9 2024
4 9 2024
2024
14 2056219 3 2024
28 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
The search for biomarkers for the early diagnosis of neurodegenerative diseases is a growing area. Numerous investigations are exploring minimally invasive and cost-effective biomarkers, with the detection of phosphorylated Tau (pTau) protein emerging as one of the most promising fields. pTau is the main component of the paired helical filaments found in the brains of Alzheimer’s disease cases and serves as a precursor in the formation of neurofibrillary tangles (NFTs). Recent research has revealed that analysis of p-Tau181, p-Tau217 and p-Tau231 in blood may be an option for detecting the preclinical stage of Alzheimer’s disease. In this study, we have analyzed the values of pTau 181 in the serum of Syrian hamsters during hibernation. Naturally, over the course of hibernation, these animals exhibit a reversible accumulation of pTau in the brain tissue, which rapidly disappears upon awakening. A biosensing system based on the interferometric optical detection method was used to measure the concentration of pTau181 protein in serum samples from Syrian hamsters. This method eliminates the matrix effect and amplifies the signal obtained by using silicon dioxide nanoparticles (SiO2 NPs) biofunctionalized with the αpTau181 antibody. Our results indicate a substantial increase in the serum concentration of pTau in threonine-181 during hibernation, which disappears completely 2–3 h after awakening. Investigating the mechanism by which pTau protein appears in the blood non-pathologically may enhance current diagnostic techniques. Furthermore, since this process is reversible, and no tangles are detected in the brains of hibernating hamsters, additional analysis may contribute to the discovery of improved biomarkers. Additionally, exploring drugs targeting pTau to prevent the formation of tangles or studying the outcomes of any pTau-targeted treatment could be valuable.

Keywords

Tau
Phosphorylation
Hibernation
Interferometric optical detection
Alzheimer’s disease
Nanoparticles
Subject terms

Biophysics
Neuroscience
Zoology
Nanoscience and technology
http://dx.doi.org/10.13039/501100014750 Universidad San Pablo - CEU FUSP-PPC-19-264E8B2F León-Espinosa G. MCIN/AEI/10.13039/501100011033; CSIC Interdisciplinary Thematic Platform - Cajal Blue Brain (PTI-BLUEBRAIN; Spain)PID2021-127924NB-I00 DeFelipe J. CIBERNED, ISCIIICB06/05/0066 DeFelipe J. Center for the Development of Industrial Technology (CDTI)SOL—00116599 Holgado M. Spanish Ministry of Economy and Competitiveness project TEC2017-84846-R, Madrid RegionalIND2019/IND-17207 Holgado M. issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

Microtubule-associated Tau protein is a key neuronal element with several different functions in the central nervous system. One of the first known functions of this protein was the stabilization of cellular microtubules through tubulin interaction and, therefore, its main role is the regulation of the cellular cytoskeleton and axonal transport. However, over the years, new functions have been described for this protein. According to recent studies, Tau could be involved in synaptic plasticity processes, cellular transcriptome regulation, or even the maintenance of DNA and RNA integrity1,2.

Although Tau is mostly expressed in the nervous system (mainly in neurons, but also in oligodendrocytes and astrocytes), it has also been found in peripheral nerves, renal tubules and other tissues and cells3,4. The interaction of Tau with tubulin, actin, or any other protein is affected by post-translational modifications. In an aqueous solution, Tau behaves as a protein with no defined secondary or tertiary structure (intrinsically disordered protein), but after modifications to certain residues, the protein may acquire alpha helix or beta sheet structures. This may have an impact on Tau localization, protein–protein interaction, or even undesirable self-aggregation. Among the possible modifications, phosphorylation is probably the one that has been most widely studied, but acetylation, deamidation, methylation, O-Glycosylation, ubiquitination, SUMOylation, oxidation, and nitration have also been proposed as key regulatory processes5.

Abnormal pTau (hyperphosphorylation) has been associated with pathology. pTau is the main component of the paired helical filaments present in the brain of Alzheimer’s disease (AD) cases and is a pre-step in the formation of NFTs, which—Together with beta-amyloid plaques— are the major neuropathological hallmarks of this disease. The mechanism of Tau aggregation leading to NFT formation remains unsolved and controversial. Currently, there are no effective treatments or neuronal regenerative drugs available to cure AD6. The lack of efficacy of the tested drugs could be explained by them being administered at too late a stage of the disease. Thus, early clinical diagnosis has recently become a well-studied field that could help to improve results after treatment. Nowadays, several research articles indicate that pTau biomarkers are suitable for evaluating the preclinical stage of AD7. Plasma pTau at threonine 181, in combination with neurofilament light and glial fibrillary acidic protein, is a promising, simple and accessible biomarkers for the screening and diagnosis of AD and age-related cognitive decline8,9. In addition, it has been described that plasma pTau181 can be used to differentiate AD from other neurodegenerative disorders10.

However, Tau phosphorylation is not always indicative of a pathological event, nor does it necessarily lead to Tau aggregation11. Natural processes, such as hibernation, elevate brain phosphorylation levels without causing apparent neurological damage12. Animals undergoing hibernation follow several metabolic adaptations and brain plastic changes, including generalized Tau phosphorylation throughout the brain (except in regions where Tau is not expressed, such as the cerebellum). It is striking that this phosphorylation disappears very rapidly when the animal wakes up, and several investigations point to a neuronal protective mechanism, deactivating certain brain functions, possibly to avoid energy expenditure or to prevent neuronal damage13. Hibernation is, therefore, an extraordinary model to study the phosphorylation/dephosphorylation events of Tau protein, since (1) it is a natural non-pathological process, (2) it does not involve the generation of transgenic animals, eliminating possible adverse effects due to genetic modification, and (3) the fast pTau clearance in the brain can indicate there is a mechanism to successfully eliminate a potential neuronal toxic element.

In the present study, we have analyzed the values of pTau181 in the serum of Syrian hamsters during hibernation and after awakening. The optical biosensing system based on the Interferometric optical detection method, which is extensively reported in the scientific literature14–18 was used to measure the concentration of pTau181 protein. This in vitro detection system, whose measurement signal is the Increased Relative in Optical Power (IROP%)19,20, has been employed previously for the detection of several markers in serum and saliva samples21,22. Silicon dioxide nanoparticles (SiO2 NPs) were used as a refractometric amplification method for higher sensitivity23, making it possible to enhance the limit of dejection and eliminating the inherent matrix effect of serum samples by performing a competitive assay—For example, for measuring total Tau protein in serum24. Other applications have also been previously described25,26. This detection system has been validated on multiple occasions with the gold standard ELISA technique, demonstrating even lower detection limits27. The detection limit of 10 pg/mL has been reached24 and can be lower and thus compared with techniques such as Single Molecule Array (SiMOA). In addition, the advantages of IODM should be highlighted, since it is a multiplexed system, which uses low sample volumes and allows the experiment to be monitored at all stages.

Materials and methods

Animals

Animal housing and maintenance protocols followed the guidelines of the Council of Europe Convention ETS123, revised as indicated in the Directive 86/609/EEC. Animal experiments were performed under protocols approved by the Institutional Animal Experiment Ethics Committee (Comité de Ética de Experimentación Animal de la Universidad CEU San Pablo, CEBA-CEU, Madrid, Spain; PROEX_203-4-21 and PROEX 165.6/21) and following ARRIVE guidelines.

All animals were anesthetized by intraperitoneal injection of sodium pentobarbital (200 mg/kg) and subsequently perfused intracardially with 0.9% saline solution followed by 4% paraformaldehyde in phosphate buffer (PB; 0.1M, pH 7.4).

Syrian hamster

In the present study, we used 16 male 3-month-old Syrian hamsters (Mesocricetus auratus) that were purchased from Janvier Labs (Le Genest-Saint-Isle, France). All experimental procedures were carried out at the animal facility of Centro de Tecnología Biomédica (CTB) from the Universidad Politécnica of Madrid (UPM), whose registration number is ES280790002070.

The animals had free access to food and water and were kept at 23 °C with an 8:16-h light/dark cycle. After the acclimatization period (4 weeks), 11 out of the 16 animals were transferred to a special chamber to artificially induce hibernation and obtain torpor and arousal experimental groups (controlling the temperature and illumination, while also allowing the hamsters to be monitored by measuring their locomotor activity). To induce a torpor state, temperature and light were gradually decreased until total darkness and a temperature of 4 °C were reached. Torpor was considered to have started after 24 h of inactivity. We considered animals to be torpid only when they had completed three full bouts of torpor (3–4 days of inactivity) before they were sacrificed by a lethal intraperitoneal injection of sodium pentobarbital (Dolethal. Vetoquinol; 200 mg/kg). We sacrificed the torpid animals on day 2 after torpor started, to make sure the animals were in deep torpor. The arousal experimental group was obtained by removing the torpid animals from the hibernation chamber and inducing their awakening 1 h before they were sacrificed. To ensure the animals were in deep torpor, their temperatures were checked using an infrared thermometer before blood collection and perfusion (n = 6; temperature 5–7.5 ºC) or arousal (n = 5; temperature: 32–35 °C). Control animals (n = 5) were housed, until sacrifice, under normal temperature conditions (not transferred to the hibernation chamber) for the same time as the torpor and arousal groups. See Ref.28 for further details.

P301 transgenic mice

In this study, we also used adult P301 transgenic mice as a control for detecting pTau181. The animals were obtained from The Jackson Laboratory (B6; C3-Tg, Prnp-MAPT*P301S, PS19Vle/J-Strain #008169) and express the human Tau protein P301S mutation (1N4R isoform), controlled by the mouse prion protein promoter. All experimental procedures were carried out at the animal facility of the San Pablo CEU University (SVA-CEU.USP, ES 280220000015). All animals were kept on a 12-h light–dark schedule with access to food and water ad libitum.

All animals were sacrificed by a lethal intraperitoneal injection of sodium pentobarbital (Dolethal. Vetoquinol 570,681.8; 200 mg/kg). Serum samples were obtained by drawing blood directly from the heart of the anesthetized animal and the volume obtained was transferred to an Eppendorf tube. Sampling took place in the morning, between 10 and 12 pm. After 4 h at room temperature, samples were centrifuged for 10 min at 2000g and the supernatant was collected for serum assays with NPs. Finally, animals were perfused intracardially with a saline solution followed by 4% paraformaldehyde (Electron Microscopy Sciences; 15714) in phosphate buffer (PB; 0.1M, pH 7.4). The brain of each animal was removed and post-fixed by immersion in the same fixative for 24 h at 4 °C. After rinsing in PB, the brains were cut in the coronal plane using a vibratome (Leica VT2100S). Serial sections (50 mm thick) were cryoprotected in 30% sucrose solution in 0.1 M PB and stored in ethylene glycol/glycerol at – 20°C until they were used for immunohistochemistry assays as described in Ref.28.

Mice genotyping

Transgenic and non-transgenic offspring were identified by DNA extraction from the animal tail and, subsequently, standard PCR was carried out using previously described human Tau P301S transgene-specific primers29.

Immunocytochemistry

For immunofluorescence experiments, free-floating sections were first rinsed 3 times (10 min per rinse) in 0.1 M PB. As paraformaldehyde fixation may mask antigenic sites, the sections were then incubated with sodium citrate buffer (10 mM Sodium Citrate, 0.05% Tween 20, pH 6.0) for 15 min at 95 °C. After washing with 0.1 M PB, samples were then preincubated for 1 h at room temperature with PB 0.25% Triton-X and 3% normal goat serum (Vector Laboratories, Burlingame, CA, USA). Thereafter, the sections were incubated for 48 h at 4 °C in the same stock solution containing the rabbit monoclonal to pTau181 antibody (Abcam, Cambridge, UK, EPR23506-107, 1:2000). After PB rinses, the sections were incubated for 1 h in biotinylated goat αRabbit-IgG (1:200; Vector Laboratories). After several washes in PB buffer, the sections were incubated for 1 h at room temperature with avidin–biotin peroxidase complex (Immuno Pure ABC, Pierce, Rockford, IL; diluted 1:125). Peroxidase activity was revealed with 0.01% hydrogen peroxide, using the chromogen 3,3′ diaminobenzidine tetrahydrochloride (Sigma-Aldrich, St Louis. MO; 0.05%). After staining, the sections were dehydrated, cleared with xylene, and cover-slipped with DEPEX (VWR, Rannor, Pennsylvania).

SiO2 NPs biofunctionalization with αpTau181

80 nm in diameter SiO2 NPs (Superior Silica, Chandler, AZ, USA) in ethanol were used for the biofunctionalization protocol. First, three washes were performed with 1 mL H2OmQ to remove all ethanol by centrifugation at 7500rpm for 20 min. In the last wash, the NPs were resuspended in 5 mM sodium carbonate buffer (Na2HCO3) (Sigma-Aldrich) and carboxyethylsilanetriol 25% silane in water (Fluorochem, UK) was added and kept under agitation for 1 h at room temperature. The same wash was then performed with H2OmQ, and in the final wash, they were resuspended in 2-Morpholinoethanesulphonic acid (MES) buffer at pH 3.5 for the addition of Ethyl(dimethylaminopropyl) carbodiimide (EDC) and N-Hydroxysuccinimid (NHS) (Sigma-Aldrich). The reaction was allowed to stand for 1 h at room temperature with agitation. After the washes, G-protein (Sigma-Aldrich) was added (500 µg/mL in H2OmQ) and left overnight at 4°C with agitation. The next day, 0.1 M diethanolamine (Sigma-Aldrich; D8885) was added as a blocker and allowed to react for 1 h at room temperature with agitation. The washes were repeated and αpTau181 antibody (Abcam, Cambridge, UK, EPR23506-107) was added (50 µg/mL); this incubation was left overnight at 4°C. Final washes were performed and the NPs were resuspended in PBS (Sigma-Aldrich) and stored at 4 °C24.

At each step of the biofunctionalization process, portions of NPs were separated to measure the size and concentration of the NPs using Dynamic Light Scattering (DLS) (Malvern Panalytical, UK).

αpTau181 NP concentration curve

KITs from 16 Biophotonic Sensing Cells (BICELLs) were immobilized with pTau181 protein (Abcam) (50 µL/mL) for 3 h in a 37°C humidity chamber. Tau protein (50 µg/mL) was also incubated as a control (Sigma-Aldrich; APREST88626). The KITs were washed with 20 mL H2OmQ and shaken in H2OmQ for 45 s. After drying with compressed air, the immobilization values were read.

The biofunctionalized NPs were then incubated at a concentration of 1 × 1010 NPs/µL and a dilution of 1:10 on the KIT coated with pTau181. They were kept in a humid chamber at 37 °C for 2 h. The NPS were then washed with 20 mL H2OmQ, kept in shaking PBS for 10 min and rinsed with 40 mL H2OmQ. Finally, after drying, ΔIROP (%) values were read. All points were measured in four replicates.

Competitive assay on hamster serum samples

KITs from 65-BICELLs were immobilized with pTau181 protein (50 µg/mL; 1.5 µL/cell) for 3 h at 37 °C in a humid chamber. Tau was immobilized (50 µg/mL) as a control protein.

NPs biofunctionalized with αpTau181 antibody at a concentration of 1 × 108 NPs/µL in PBS were doped with different concentrations of pTau181 protein (from 100 µg/mL to 0.00001 µg/mL in 1:10 dilutions) for 1 h at room temperature with shaking. After washes, they were incubated in the KIT (1.5 µL/cell) for 2 h in a humidity chamber at 37 °C. Finally, they were washed with 20 mL H2OmQ, kept in PBS with agitation for 10 min, and then rinsed with 40 mL H2OmQ.

These NPs were incubated with the hamster serum samples (1:10 dilution) for 1 h at room temperature with agitation. We used 16 different serum samples: 5 samples from control hamsters (non-hibernating), 5 samples from arousal hamsters, and 6 samples from torpor hamsters. In addition, as a positive control, the biofunctionalized NPs were incubated with 4 samples from transgenic P301S mice. The KITs were washed and incubated in the same manner as the concentration standard. All measurements were performed in five replicates (Fig. 4). One-way ANOVA statistical analysis was performed with a Tukey’s comparison and a Levene’s test of homogeneity of variance with a significance level of p < 0.01.

Results

Since blood pTauT181 detection is considered as a suitable biomarker to evaluate the preclinical stage of AD, we used a biosensing system, based on the interferometric optical detection method, to monitor the Tau phosphorylation at T181 in the bloodstream during the hibernation of the Syrian hamster. This experimental model has been extensively used to study Tau phosphorylation in the brain30–32.

First, the NPs undergo a biofunctionalization process by modifying their surface and adding the antibody of interest (αpTau181). After this process, the NPs are incubated with the serum samples, so the protein present in the sample will bind to the NPs. After separating this fraction of NPs, they are incubated on the surface of the biosensor previously coated with the pTau181 protein. In this way, the free antibodies of the NPs will bind with the protein immobilized on the biosensor, obtaining a higher IROP (%) signal when the pTau181 protein in the sample is less concentrated. See a schematic representation of this process in Fig. 1.Fig. 1 Schematic representation of the steps followed to perform the competitive assay for pTau181 detection. Created with BioRender.com.

SiO2 NPs biofunctionalization with αpTau181

80 nm SiO2 NPs were biofunctionalized with the αpTau181 antibody using a silanization protocol and G-protein. During this process, each step was verified by DLS to measure the concentration and size of the NPs.

Table 1 shows the NP size and how it increases as we progress in the biofunctionalization protocol (Fig. 2). Also shown are the concentration of the NPs after each step and the final working concentration of the NPs once they are biofunctionalized.Table 1 NPs concentrations and size during the biofunctionalization process.

	Initial	G-Protein	αp181Tau	
Size (nm)	78.81 ± 3.35	101.30 ± 4.50	141.60 ± 2.88	
Concentration (NPs/µL)	4.33 × 1010	2.16 × 1010	5.42 × 109	

Fig. 2 DLS measurements of the hydrodynamic diameter of the NPs during the biofunctionalization protocol.

αpTau181 NPs concentration curve

Following the biofunctionalization protocol, the NPs were incubated on the biofunctionalized KITs with pTau181 protein and Tau at a concentration of 5.42 × 109 and 1:10 and 1:100 dilutions (1.5 µL/cell).

After incubation, the KITs were washed and the ΔIROP (%) signals were read (Fig. 3), obtaining a curve in which the signal decreases as the concentration of NPs decreases. In addition, it is observed that the NPs have specificity on the surface covered with pTau181 protein since a very low background signal is obtained on the Tau protein.Fig. 3 Concentration curve of NPs biofunctionalized with pTau181 antibody.

Competitive assay on hamster serum samples

After testing the functionality of the NPs, a competitive assay was performed. For this purpose, the NPs were incubated at a concentration of 1 × 109 NPs/µL with different concentrations of pTau181 protein (from 100 to 0.00001 µg/mL in 1:10 dilutions) and left at a final concentration of 1 × 108 NPs/µL. After the incubation time, they were applied to the sensor surface coated with pTau181 and left to incubate for the calibration curve.

At the same time, hamster serum samples (1:10 dilution) were incubated with the NPs at a final concentration of 1 × 108 NPs/µL and the same procedure as for the calibration curve was followed. Serum from transgenic mice were incubated as a positive control.

Once the ΔIROP (%) signals of the NPs were read, the calibration curve was obtained (Fig. 4), in which the signals obtained from the samples were extrapolated to determine the concentration of pTau181 protein in the serum of hamster and transgenic mice (Table 2).Fig. 4 Calibration curve of the competitive assay to determine pTau181.

Table 2 Data of p181Tau protein concentration in hamster and in P301 mouse serum once extrapolated on the calibration curve.

Serum sample	Concentration (µg/mL)	Serum sample	Concentration (µg/mL)	
Control 1	8.65	Arousal 4	8.22	
Control 2	16.45	Arousal 5	7.03	
Control 3	11.28	Torpor 1	41.00	
Control 4	5.70	Torpor 2	102.78	
Control 5	3.08	Torpor 3	34.75	
Arousal 1	2.19	Torpor 4	44.68	
Arousal 2	1.24	Torpor 5	50.51	
Arousal 3	1.91	Torpor 6	80.56	
Transgenic mouse 1	137.79	Transgenic mouse 3	148.38	
Transgenic mouse 2	214.20	Transgenic mouse 4	143.42	

Analyzing the results, noticeable differences emerge between the control samples, exhibiting levels ranging from 3 to 16 µg/mL, and the samples obtained from torpor hamsters, which display a pTau181 concentration between 35 and 100 µg/mL. Conversely, arousal hamsters have concentrations similar to the controls. This alignment with control levels is plausible, as the animals should activate the Tau protein dephosphorylation machinery upon cessation of hibernation, a process that is inactive during hibernation.

On the other hand, the positive controls of the transgenic mice also present high concentrations of pTau181 protein (140–200 µg/mL). This would be expected, since these P301 transgenic mice express the human Tau protein P301S mutation (1N4R isoform), leading to early symptoms of human tauopathies such as cognitive decline. Additionally, they promote a progressive accumulation of filamentous Tau in association with neuron loss33–35.

Figure 5 shows the box plot obtained after performing the One-Way ANOVA statistical analysis with a Tukey’s comparison of means and a Levene’s test of homogeneity of variance with a significance level of p < 0.01. As shown, there are significant differences in the concentration of pTau181 protein between control and torpor hamsters, as well as between torpor and arousal hamsters.Fig. 5 Comparison of pTau181 protein concentration in control, torpor, and arousal hamsters. ***p < 0.01.

Immunohistochemistry assay using αpTau 181 antibody

Previous studies evaluating the effect of hibernation on Tau protein revealed that, during the torpor state, Tau is phosphorylated at several residues. Increased labeling has been detected during torpor in western blot assays using the antibodies AT100, AT180, AT270, PHF-1, and 12E8. These antibodies recognize different phosphorylated amino acids at positions 212/214, 181, 231, 396, and 262/356, respectively. However, the presence of pTau has only been demonstrated by immunohistochemistry using the AT8 antibody, which recognizes phosphorylated Tau at the S202/T205 epitope. To further investigate the presence of pTau in the brain of hibernating Syrian hamsters, we performed immunohistochemistry assays using the same specific antibody used here for serum pTau detection (pTau181). Figure 6 shows the labeling in the neocortex and hippocampus in the Syrian hamster brain for different states: torpor, arousal, and non-hibernating (control). As expected, there is no appreciable labeling of pTau181 in control animals, whereas in the torpor state, a clear labeling is observed in hippocampal neurons (Fig. 6K) and in the apical dendrites of pyramidal neurons in the neocortex (Fig. 6J), as previously described using AT8 antibody36. Also, in line with previous western blot results12, pTau181 phosphorylation labeling was fully reversible after arousal (Fig. 6E,H). These results are in accordance with the pTau 181 serum levels found in the same animals.Fig. 6 Photomicrographs showing the pattern of hyperphosphorylated Tau immunostaining with pTau181 antibody in control (A,D,G), arousal (B,E,H), and torpid (C,F,I,J) Syrian hamsters. Small, squared zones in (D–F) are shown at higher magnification in (G–J). Black arrows in (I) indicate pTau181-ir bundles of apical dendrites. Black arrows in (J) indicate 181-positive dentate gyrus neurons, whereas red arrows indicate CA3 pTau181-ir neurons. Scale bar in J indicates 115 μm in (A–F), and 57 μm in (G–J). Adobe Photoshop CS4 software was used to compose figures.

Discussion

In recent years, much progress has been made in the development of early diagnostic techniques for neurodegenerative diseases, specifically for AD. Cerebrospinal fluid (CSF) analysis and PET imaging, although highly accurate, are expensive and invasive procedures. It has been reported that the amount and phosphorylation of CSF Tau correlate with AD state and the amyloid load37. Currently, plasma and genetic markers may be combined in search of an early diagnosis, allowing a relatively easy and non-invasive approach. One of the most commonly used plasma biomarkers is phosphorylated Tau at threonine 181, which can be used to accurately differentiate AD from other non-AD neurodegenerative diseases38. This biomarker may also be used to predict pre-dementia or even the presymptomatic stage of AD39. Other biomarkers can be used together to detect AD at the earliest possible stage. Concerning this, ultrasensitive immunoassays allow the measurement of several pTau isoforms, such as pTau181, pTau217, and pTau231, which are the most promising AD biomarkers in plasma. In addition, a recent research article suggested that NfL and GFAP can also be used to improve diagnostic accuracy40. Therefore, efforts are focused on developing Alzheimer’s blood tests for primary care, providing an inexpensive and accurate means to predict the risk of developing AD.

In this study, a competitive assay was conducted to determine the concentration of pTau181 protein in serum samples from a Syrian hamster hibernation model.

The key finding is that phosphorylated Tau at threonine 181, one of the most promising AD biomarkers, is present in the serum of hibernating Syrian hamsters and fully disappears during arousal.

Unlike human AD cases, the Syrian hamster does not show any known pathologies due to elevated pTau levels in the brain or serum. This raises the question: why is Tau secreted into the bloodstream? Currently, the presence of Tau protein in the blood of AD patients can be attributed to (1) the release of brain pTau into the extracellular space upon neuronal death, (2) abnormal neuronal pTau secretion under a pathological condition, and/or (3) pTau transport from peripheral tissues to the bloodstream. Concerning the third point, Barthélemy et al. indicated that peripheral contribution has a different phosphorylation pattern compared to CSF and this may affect the search for pTau biomarkers10. Some studies have shown that truncated Tau species appear in brain lysates and CSF of AD cases41. Truncation is critical in the N-terminal region, playing a role in the progression of AD, as this may improve the misfolding/aggregation and lead to neurodegeneration41,42. Future studies are needed to determine whether Syrian hamster blood contains the same Tau truncated species, as this could explain why it does not promote any pathological event. It has been described that phosphorylated Tau can be delivered from neuronal cells transported in exosomes. This mechanism could be responsible for the slow Tau propagation or spreading to other brain regions in AD43 and might explain the pTau transport from cells to the bloodstream.

The augmented pTau levels detected here in serum are not associated with any pathological event, which opens up new questions regarding the mechanism of Tau protein diffusion in the organism. Since tau protein is predominantly found in the brain, the presence of pTau in serum most likely has this origin. If so, this would indicate transport across the blood–brain barrier during hibernation in a reversible way, which would be a surprising finding. In general, this work may help to better understand neurodegenerative diseases and improve preclinical diagnostic methods for tauopathies.

Finally, the present results may be useful for exploring immunotherapy approaches targeting pTau, which could help prevent the formation of tau tangles and offer a potential therapeutic avenue for tauopathies.

Acknowledgements

We would like to thank Pablo Orduña Méndez for his technical assistance and to Nick Guthrie for his excellent editorial assistance.

Author contributions

M.H, G. LE and J.D designed the research, A.MM and G.LE conducted experiments and analyzed the data obtained. All authors interpreted the data and wrote the manuscript.

Funding

The funding was supported by Universidad San Pablo—CEU, FUSP-PPC-19-264E8B2F, MCIN/AEI/10.13039/501100011033; CSIC Interdisciplinary Thematic Platform—Cajal Blue Brain (PTI-BLUEBRAIN; Spain), PID2021-127924NB-I00 funded by MCIN/AEI/10.13039/501100011033, CIBERNED, ISCIII, CB06/05/0066, Center for the Development of Industrial Technology (CDTI), SOL—00116599, Spanish Ministry of Economy and Competitiveness project TEC2017-84846-R, Madrid Regional, IND2019/IND-17207.

Data availability

Data supporting the findings of the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare no competing interests.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors contributed equally: G. León-Espinosa and Ana María Martín Murillo.
==== Refs
References

1. Anton-Fernandez A Valles-Saiz L Avila J Hernandez F Neuronal nuclear tau and neurodegeneration Neuroscience 2023 518 178 184 10.1016/j.neuroscience.2022.07.015 35872252
Anton-Fernandez, A., Valles-Saiz, L., Avila, J. & Hernandez, F. Neuronal nuclear tau and neurodegeneration. Neuroscience 518, 178–184 (2023).35872252 10.1016/j.neuroscience.2022.07.015
2. Sotiropoulos I Atypical, non-standard functions of the microtubule associated Tau protein Acta Neuropathol. Commun. 2017 5 91 96 10.1186/s40478-017-0489-6 29187252
Sotiropoulos, I. et al. Atypical, non-standard functions of the microtubule associated Tau protein. Acta Neuropathol. Commun. 5, 91–96 (2017).29187252 10.1186/s40478-017-0489-6
3. Alam O A single-cell-type transcriptomics map of human tissues Nat. Genet. 2021 53 1275 1284 34493864
Alam, O. A single-cell-type transcriptomics map of human tissues. Nat. Genet. 53, 1275–1284 (2021).34493864
4. Thul PJ Lindskog C The human protein atlas: A spatial map of the human proteome Protein Sci. 2018 27 233 244 10.1002/pro.3307 28940711
Thul, P. J. & Lindskog, C. The human protein atlas: A spatial map of the human proteome. Protein Sci. 27, 233–244 (2018).28940711 10.1002/pro.3307
5. Alquezar C Arya S Kao AW Tau post-translational modifications: dynamic transformers of Tau function, degradation, and aggregation Front. Neurol. 2021 11 595532 10.3389/fneur.2020.595532 33488497
Alquezar, C., Arya, S. & Kao, A. W. Tau post-translational modifications: dynamic transformers of Tau function, degradation, and aggregation. Front. Neurol. 11, 595532 (2021).33488497 10.3389/fneur.2020.595532
6. Conti Filho CE Advances in Alzheimer's disease's pharmacological treatment Front. Pharmacol. 2023 14 1101452 10.3389/fphar.2023.1101452 36817126
Conti Filho, C. E. et al. Advances in Alzheimer’s disease’s pharmacological treatment. Front. Pharmacol. 14, 1101452 (2023).36817126 10.3389/fphar.2023.1101452
7. Nam E Lee Y Moon C Chang K Serum Tau proteins as potential biomarkers for the assessment of Alzheimer's disease progression Int. J. Mol. Sci. 2020 21 5007 10.3390/ijms21145007 32679907
Nam, E., Lee, Y., Moon, C. & Chang, K. Serum Tau proteins as potential biomarkers for the assessment of Alzheimer’s disease progression. Int. J. Mol. Sci. 21, 5007 (2020).32679907 10.3390/ijms21145007
8. Gonzalez-Ortiz F Plasma phospho-tau in Alzheimer's disease: Towards diagnostic and therapeutic trial applications Mol. Neurodegen. 2023 18 18 28 10.1186/s13024-023-00605-8
Gonzalez-Ortiz, F. et al. Plasma phospho-tau in Alzheimer’s disease: Towards diagnostic and therapeutic trial applications. Mol. Neurodegen. 18, 18–28 (2023).10.1186/s13024-023-00605-8
9. Saunders TS Predictive blood biomarkers and brain changes associated with age-related cognitive decline Brain Commun. 2023 5 fcad113 10.1093/braincomms/fcad113 37180996
Saunders, T. S. et al. Predictive blood biomarkers and brain changes associated with age-related cognitive decline. Brain Commun. 5, fcad113 (2023).37180996 10.1093/braincomms/fcad113
10. Barthelemy NR Horie K Sato C Bateman RJ Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease J. Exp. Med. 2020 217 e20200861 10.1084/jem.20200861 32725127
Barthelemy, N. R., Horie, K., Sato, C. & Bateman, R. J. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease. J. Exp. Med. 217, e20200861 (2020).32725127 10.1084/jem.20200861
11. Wegmann S Biernat J Mandelkow E A current view on Tau protein phosphorylation in Alzheimer's disease Curr. Opin. Neurobiol. 2021 69 131 138 10.1016/j.conb.2021.03.003 33892381
Wegmann, S., Biernat, J. & Mandelkow, E. A current view on Tau protein phosphorylation in Alzheimer’s disease. Curr. Opin. Neurobiol. 69, 131–138 (2021).33892381 10.1016/j.conb.2021.03.003
12. Arendt T Reversible paired helical filament-like phosphorylation of tau is an adaptive process associated with neuronal plasticity in hibernating animals J. Neurosci. 2003 23 6972 6981 10.1523/JNEUROSCI.23-18-06972.2003 12904458
Arendt, T. et al. Reversible paired helical filament-like phosphorylation of tau is an adaptive process associated with neuronal plasticity in hibernating animals. J. Neurosci. 23, 6972–6981 (2003).12904458 10.1523/JNEUROSCI.23-18-06972.2003
13. Arendt T Bullmann T Neuronal plasticity in hibernation and the proposed role of the microtubule-associated protein tau as a "master switch" regulating synaptic gain in neuronal networks Am. J. Physiol. Regul. Integr. Comp. Physiol. 2013 305 478 10.1152/ajpregu.00117.2013
Arendt, T. & Bullmann, T. Neuronal plasticity in hibernation and the proposed role of the microtubule-associated protein tau as a “master switch” regulating synaptic gain in neuronal networks. Am. J. Physiol. Regul. Integr. Comp. Physiol. 305, 478 (2013).10.1152/ajpregu.00117.2013
14. Casquel R Engineering vertically interrogated interferometric sensors for optical label-free biosensing Anal. Bioanal Chem. 2020 412 3285 3297 10.1007/s00216-020-02411-3 32055908
Casquel, R. et al. Engineering vertically interrogated interferometric sensors for optical label-free biosensing. Anal. Bioanal Chem. 412, 3285–3297 (2020).32055908 10.1007/s00216-020-02411-3
15. Santamaria B Development towards compact nitrocellulose-based interferometric biochips for dry eye MMP9 label-free in-situ diagnosis Sensors (Basel) 2017 17 1158 10.3390/s17051158 28534808
Santamaria, B. et al. Development towards compact nitrocellulose-based interferometric biochips for dry eye MMP9 label-free in-situ diagnosis. Sensors (Basel) 17, 1158 (2017).28534808 10.3390/s17051158
16. Holgado M Description of an advantageous optical label-free biosensing interferometric read-out method to measure biological species Sensors (Basel) 2014 14 3675 3689 10.3390/s140203675 24566633
Holgado, M. et al. Description of an advantageous optical label-free biosensing interferometric read-out method to measure biological species. Sensors (Basel) 14, 3675–3689 (2014).24566633 10.3390/s140203675
17. Lavín Á Efficient design and optimization of bio-photonic sensing cells (BICELLs) for label free biosensing Sens. Actuators B Chem. 2013 176 753 760 10.1016/j.snb.2012.09.058
Lavín, Á. et al. Efficient design and optimization of bio-photonic sensing cells (BICELLs) for label free biosensing. Sens. Actuators B Chem. 176, 753–760 (2013).10.1016/j.snb.2012.09.058
18. Sanza FJ Bio-photonic sensing cells over transparent substrates for anti-gestrinone antibodies biosensing Biosens. Bioelectron. 2011 26 4842 4847 10.1016/j.bios.2011.06.010 21733669
Sanza, F. J. et al. Bio-photonic sensing cells over transparent substrates for anti-gestrinone antibodies biosensing. Biosens. Bioelectron. 26, 4842–4847 (2011).21733669 10.1016/j.bios.2011.06.010
19. Holgado M Towards reliable optical label-free point-of-care (PoC) biosensing devices Sens. Actuators B Chem. 2016 236 765 772 10.1016/j.snb.2016.06.047
Holgado, M. et al. Towards reliable optical label-free point-of-care (PoC) biosensing devices. Sens. Actuators B Chem. 236, 765–772 (2016).10.1016/j.snb.2016.06.047
20. Maigler M A new device based on interferometric optical detection method for label-free screening of C-reactive protein IEEE Trans. Instrum. Meas. 2018 68 3193 3199 10.1109/TIM.2018.2876073
Maigler, M. et al. A new device based on interferometric optical detection method for label-free screening of C-reactive protein. IEEE Trans. Instrum. Meas. 68, 3193–3199 (2018).10.1109/TIM.2018.2876073
21. Murillo AMM Integration of multiple interferometers in highly multiplexed diagnostic KITs to evaluate several biomarkers of COVID-19 in serum Biosensors (Basel) 2022 12 671 10.3390/bios12090671 36140055
Murillo, A. M. M. et al. Integration of multiple interferometers in highly multiplexed diagnostic KITs to evaluate several biomarkers of COVID-19 in serum. Biosensors (Basel) 12, 671 (2022).36140055 10.3390/bios12090671
22. Murillo AMM Developing an optical interferometric detection method based biosensor for detecting specific SARS-CoV-2 immunoglobulins in serum and saliva, and their corresponding ELISA correlation Sens. Actuators B Chem. 2021 345 130394 10.1016/j.snb.2021.130394 34248283
Murillo, A. M. M. et al. Developing an optical interferometric detection method based biosensor for detecting specific SARS-CoV-2 immunoglobulins in serum and saliva, and their corresponding ELISA correlation. Sens. Actuators B Chem. 345, 130394 (2021).34248283 10.1016/j.snb.2021.130394
23. Bolaños, M. H. et al. U.S. Patent Application No. 17/781,697 (2023).
24. Murillo AMM A new optical interferometric biosensing system enhanced with nanoparticles for Alzheimer's disease in serum Biosensors (Basel) 2023 13 707 10.3390/bios13070707 37504106
Murillo, A. M. M. et al. A new optical interferometric biosensing system enhanced with nanoparticles for Alzheimer’s disease in serum. Biosensors (Basel) 13, 707 (2023).37504106 10.3390/bios13070707
25. Espinosa RL A new optical interferometric-based in vitro detection system for the specific IgE detection in serum of the main peach allergen Biosens. Bioelectron. 2020 169 112641 10.1016/j.bios.2020.112641 32992160
Espinosa, R. L. et al. A new optical interferometric-based in vitro detection system for the specific IgE detection in serum of the main peach allergen. Biosens. Bioelectron. 169, 112641 (2020).32992160 10.1016/j.bios.2020.112641
26. Valle LG Developing an improved optical biosensing system based on gold nanoparticles acting as interferometric enhancers in Lactoferrin detection Analyst 2023 148 5445 5455 10.1039/D3AN01328F 37750047
Valle, L. G. et al. Developing an improved optical biosensing system based on gold nanoparticles acting as interferometric enhancers in Lactoferrin detection. Analyst 148, 5445–5455 (2023).37750047 10.1039/D3AN01328F
27. Murillo AMM Reports on the sensitivity enhancement in interferometric based biosensors by biotin-streptavidin system Heliyon 2023 9 12 10.1016/j.heliyon.2023.e23123
Murillo, A. M. M. et al. Reports on the sensitivity enhancement in interferometric based biosensors by biotin-streptavidin system. Heliyon 9, 12 (2023).10.1016/j.heliyon.2023.e23123
28. Anton-Fernandez A Leon-Espinosa G DeFelipe J Munoz A Changes in the Golgi apparatus of neocortical and hippocampal neurons in the hibernating hamster Front. Neuroanat. 2015 9 157 10.3389/fnana.2015.00157 26696838
Anton-Fernandez, A., Leon-Espinosa, G., DeFelipe, J. & Munoz, A. Changes in the Golgi apparatus of neocortical and hippocampal neurons in the hibernating hamster. Front. Neuroanat. 9, 157 (2015).26696838 10.3389/fnana.2015.00157
29. Largo-Barrientos P Lowering Synaptogyrin-3 expression rescues Tau-induced memory defects and synaptic loss in the presence of microglial activation Neuron 2021 109 767 777.e5 10.1016/j.neuron.2020.12.016 33472038
Largo-Barrientos, P. et al. Lowering Synaptogyrin-3 expression rescues Tau-induced memory defects and synaptic loss in the presence of microglial activation. Neuron 109, 767-777.e5 (2021).33472038 10.1016/j.neuron.2020.12.016
30. Dujardin S Colin M Buee L Invited review: Animal models of tauopathies and their implications for research/translation into the clinic Neuropathol. Appl. Neurobiol. 2015 41 59 80 10.1111/nan.12200 25428793
Dujardin, S., Colin, M. & Buee, L. Invited review: Animal models of tauopathies and their implications for research/translation into the clinic. Neuropathol. Appl. Neurobiol. 41, 59–80 (2015).25428793 10.1111/nan.12200
31. Feketa VV Bagriantsev SN Gracheva EO Ground squirrels—Experts in thermoregulatory adaptation Trends Neurosci. 2023 46 505 507 10.1016/j.tins.2023.04.008 37188617
Feketa, V. V., Bagriantsev, S. N. & Gracheva, E. O. Ground squirrels—Experts in thermoregulatory adaptation. Trends Neurosci. 46, 505–507 (2023).37188617 10.1016/j.tins.2023.04.008
32. Wu C Storey KB Life in the cold: Links between mammalian hibernation and longevity Biomol. Concepts 2016 7 41 52 10.1515/bmc-2015-0032 26820181
Wu, C. & Storey, K. B. Life in the cold: Links between mammalian hibernation and longevity. Biomol. Concepts 7, 41–52 (2016).26820181 10.1515/bmc-2015-0032
33. Takeuchi H P301S mutant human tau transgenic mice manifest early symptoms of human tauopathies with dementia and altered sensorimotor gating PLoS One 2011 6 e21050 10.1371/journal.pone.0021050 21698260
Takeuchi, H. et al. P301S mutant human tau transgenic mice manifest early symptoms of human tauopathies with dementia and altered sensorimotor gating. PLoS One 6, e21050 (2011).21698260 10.1371/journal.pone.0021050
34. Macdonald JA Assembly of transgenic human P301S Tau is necessary for neurodegeneration in murine spinal cord Acta Neuropathol. Commun. 2019 7 44 45 10.1186/s40478-019-0695-5 30885267
Macdonald, J. A. et al. Assembly of transgenic human P301S Tau is necessary for neurodegeneration in murine spinal cord. Acta Neuropathol. Commun. 7, 44–45 (2019).30885267 10.1186/s40478-019-0695-5
35. Yoshiyama Y Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model Neuron 2007 53 337 351 10.1016/j.neuron.2007.01.010 17270732
Yoshiyama, Y. et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337–351 (2007).17270732 10.1016/j.neuron.2007.01.010
36. Leon-Espinosa G Changes in Tau phosphorylation in hibernating rodents J. Neurosci. Res. 2013 91 954 962 10.1002/jnr.23220 23606524
Leon-Espinosa, G. et al. Changes in Tau phosphorylation in hibernating rodents. J. Neurosci. Res. 91, 954–962 (2013).23606524 10.1002/jnr.23220
37. Wattmo C Blennow K Hansson O Cerebro-spinal fluid biomarker levels: Phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease BMC Neurol. 2020 20 10 10.1186/s12883-019-1591-0 31918679
Wattmo, C., Blennow, K. & Hansson, O. Cerebro-spinal fluid biomarker levels: Phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease. BMC Neurol. 20, 10 (2020).31918679 10.1186/s12883-019-1591-0
38. Janelidze S Plasma P-tau181 in Alzheimer's disease: Relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia Nat. Med. 2020 26 379 386 10.1038/s41591-020-0755-1 32123385
Janelidze, S. et al. Plasma P-tau181 in Alzheimer’s disease: Relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia. Nat. Med. 26, 379–386 (2020).32123385 10.1038/s41591-020-0755-1
39. Giacomucci G Plasma p-tau181 as a promising non-invasive biomarker of Alzheimer's disease pathology in subjective cognitive decline and mild cognitive impairment J. Neurol. Sci. 2023 453 120805 10.1016/j.jns.2023.120805 37716237
Giacomucci, G. et al. Plasma p-tau181 as a promising non-invasive biomarker of Alzheimer’s disease pathology in subjective cognitive decline and mild cognitive impairment. J. Neurol. Sci. 453, 120805 (2023).37716237 10.1016/j.jns.2023.120805
40. Kivisakk P Plasma biomarkers for diagnosis of Alzheimer's disease and prediction of cognitive decline in individuals with mild cognitive impairment Front. Neurol. 2023 14 1069411 10.3389/fneur.2023.1069411 36937522
Kivisakk, P. et al. Plasma biomarkers for diagnosis of Alzheimer’s disease and prediction of cognitive decline in individuals with mild cognitive impairment. Front. Neurol. 14, 1069411 (2023).36937522 10.3389/fneur.2023.1069411
41. Amadoro G Latina V Corsetti V Calissano P N-terminal tau truncation in the pathogenesis of Alzheimer's disease (AD): Developing a novel diagnostic and therapeutic approach Biochim. Biophys. Acta Mol. Basis Dis. 2020 1866 165584 10.1016/j.bbadis.2019.165584 31676377
Amadoro, G., Latina, V., Corsetti, V. & Calissano, P. N-terminal tau truncation in the pathogenesis of Alzheimer’s disease (AD): Developing a novel diagnostic and therapeutic approach. Biochim. Biophys. Acta Mol. Basis Dis. 1866, 165584 (2020).31676377 10.1016/j.bbadis.2019.165584
42. Gu J Truncation of Tau selectively facilitates its pathological activities J. Biol. Chem. 2020 295 13812 13828 10.1074/jbc.RA120.012587 32737201
Gu, J. et al. Truncation of Tau selectively facilitates its pathological activities. J. Biol. Chem. 295, 13812–13828 (2020).32737201 10.1074/jbc.RA120.012587
43. Perez M Avila J Hernandez F Propagation of Tau via extracellular vesicles Front. Neurosci. 2019 13 698 10.3389/fnins.2019.00698 31312118
Perez, M., Avila, J. & Hernandez, F. Propagation of Tau via extracellular vesicles. Front. Neurosci. 13, 698 (2019).31312118 10.3389/fnins.2019.00698
